EANS-News: ALAPIS ANNOUNCES ITS SHARE CAPITAL INCREASE TO RAISE c. EUR451.1 MILLION

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY
IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA OR
JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR
DISTRIBUTION WOULD BE UNLAWFUL
THIS ANNOUNCEMENT IS NOT A PROSPECTUS
AND IS NOT AN OFFER TO SELL OR A SOLICITATION OF ANY OFFER TO BUY ANY
SECURITIES IN THE UNITED STATES OR IN ANY OTHER JURISDICTION.

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

pharmaceuticals

Athen (euro adhoc) - Athens, 6 August 2009 - Alapis S.A. ("Alapis" or
"the Company") announces that, on 5 August, 2009, the Company´s Board
of Directors approved a share capital increase by way of pre-emptive
rights for existing shareholders that will increase the Company´s
share capital by EUR294,180,066. The share capital increase will be
effected through the issue of 980,600,220 new ordinary shares of a
nominal value EUR0.30 each, with payment in cash.

Shareholders of Alapis will be entitled to one subscription right for
each existing share held. The exercise of one subscription right will
entitle the holder to subscribe for one new share at the proposed
subscription price of EUR0.46 per new share. In addition, those who
will exercise their subscription rights will be entitled to subscribe
for a number of additional new shares at the subscription price
(oversubscription rights). The total gross proceeds will amount to
approximately EUR451.1 million.

The Company intends to use the net proceeds from the share capital
increase to repay part of its existing short-term debt, finance
expected working capital requirements and pursue targeted
acquisitions of companies and other assets, in order to further
support its growth strategy in the Greek and South-Eastern European
healthcare markets.

Alapis has been informed that Lamda Partners L.P., a private equity
fund, has irrevocably undertaken to participate in the share capital
increase through one or more of its wholly owned subsidiaries by
investing approximately EUR90.2 million through the exercise of
196,120,044 rights, representing 20% of the new ordinary shares. Such
rights will be acquired from Dr. Lavrentis Lavrentiadis or in the
open market. The Company was also informed that Dr.Lavrentiadis is a
director of the general partner of Lamda Partners L.P.

A syndicate of international firms composed of ABN AMRO, BofA Merrill
Lynch, BNP PARIBAS, Deutsche Bank AG London Branch and Jefferies has
agreed to subscribe or procure subscribers for any new shares which
may remain unsubscribed at the end of the subscription period,
subject to customary terms and conditions.

The Company´s prospectus that will be prepared in relation to the
share capital increase will be subject to approval by the Hellenic
Capital Market Commission. The Company will endeavour to complete the
capital increase by the end of September, subject to obtaining all
regulatory and other approvals in a timely manner.

The decision of the Board of Directors is pursuant to the authority
given to it by the second repeat Extraordinary General Meeting of
Alapis´ shareholders held on 29 September 2008.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: ALAPIS S.A.
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Norbert Schmidt-Gollas

n.gollas@alapis.eu

www.alapis.eu

Alapis

Aftokratoros Nikolaou str., No 2,

p.c.176 71 Athens

tel. 0030 213-0175000-1

fax 0030 210-9238460

Branche: Pharmaceuticals
ISIN: GRS322003013
WKN: A0MSVZ
Börsen: Berlin / free trade